Business Context and Reporting Period
This Form 8-K, dated August 4, 2025, reports on the results of an Extraordinary General Meeting held by Helix Acquisition Corp. II ("Helix"). The filing details the shareholder approval of a business combination with The Ras, Inc. (d/b/a BridgeBio Oncology Therapeutics, or "BBOT"). Upon consummation, the combined entity will be renamed "BridgeBio Oncology Therapeutics, Inc." and will be domesticated from the Cayman Islands to Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and transaction approval; it does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The filing text does not provide a clear value for specific financial performance indicators.
Material Changes and Voting Results
Shareholders approved eight key proposals to facilitate the merger and reorganization. A total of 19,407,670 shares (82.55% of outstanding shares) were present at the meeting.
- Business Combination Proposal: Approved with 17,311,423 votes FOR and 2,096,247 votes AGAINST.
- Domestication Proposal: Approved unanimously (4,600,000 FOR, 0 AGAINST) to transfer incorporation to Delaware.
- Stock Issuance Proposal: Approved with 17,311,423 votes FOR and 2,096,247 votes AGAINST, authorizing issuance to BBOT shareholders and PIPE investors.
- Organizational Documents: Approved to adopt new charter and bylaws, including a name change to BridgeBio Oncology Therapeutics, Inc.
- Advisory Proposals: Shareholders approved changes to authorized shares, exclusive forum provisions, supermajority vote requirements, director removal standards, and the prohibition of written consent actions.
- Compensation Plans: Approved the 2025 Stock Option and Incentive Plan and the 2025 Employee Stock Purchase Plan.
- Director Elections: Unanimously elected eight directors, including Eli Wallace, Neil Kumar, Frank McCormick, Praveen Tipirneni, Michelle Doig, Bihua Chen, Raymond Kelleher, and Jake Bauer.
Guidance, Outlook, and Risks
Management provided forward-looking statements regarding the expected cash runway, financing proceeds, and clinical trial timelines for BBOT's product candidates (including ONKORAS-101, BREAKER-101, BBO-11818, BBO-8520, and BBO-10203). The filing explicitly states that these are not guarantees of future performance.
Key Risks Identified:
- Uncertainty regarding the outcomes of ongoing clinical trials and regulatory approvals.
- Risks related to the ability to consummate the business combination, including potential regulatory delays or conditions.
- Competition from other product candidates and the ability to source raw materials.
- Intellectual property claims and the ability to attract and retain qualified personnel.
- Market and economic conditions affecting the combined company.
Investor Verification Checklist
- Verify the final closing date of the business combination and the exact exchange listing details for the new "BridgeBio Oncology Therapeutics, Inc." ticker.
- Review the definitive Proxy Statement/Prospectus (File No. 333-288222) for detailed financial projections and the specific terms of the PIPE investment.
- Confirm the status of regulatory approvals required for the domestication and merger.
- Monitor upcoming clinical data readouts for ONKORAS-101 and BREAKER-101 as cited in the forward-looking statements.
- Check for any subsequent filings regarding the redemption of Helix public shares prior to the final closing.